Agilent Applied sciences (A) reported $1.7 billion in income for the quarter ended October 2024, representing a year-over-year enhance of 0.8%. EPS of $1.46 for a similar interval compares to $1.38 a yr in the past.
The reported income compares to the Zacks Consensus Estimate of $1.67 billion, representing a shock of +1.65%. The corporate delivered an EPS shock of +3.55%, with the consensus EPS estimate being $1.41.
Whereas traders intently watch year-over-year adjustments in headline numbers — income and earnings — and the way they evaluate to Wall Avenue expectations to find out their subsequent plan of action, some key metrics at all times present a greater perception into an organization’s underlying efficiency.
As these metrics affect top- and bottom-line efficiency, evaluating them to the year-ago numbers and what analysts estimated helps traders mission a inventory’s worth efficiency extra precisely.
Right here is how Agilent carried out within the simply reported quarter by way of the metrics most generally monitored and projected by Wall Avenue analysts:
- Income by Finish Markets- Pharmaceutical: $595 million in comparison with the $583.30 million common estimate based mostly on two analysts. The reported quantity represents a change of +0.9% yr over yr.
- Income by Finish Markets- Academia and Authorities: $150 million versus the two-analyst common estimate of $138.29 million. The reported quantity represents a year-over-year change of 0%.
- Income by Finish Markets- Diagnostics and Scientific: $255 million in comparison with the $243.48 million common estimate based mostly on two analysts. The reported quantity represents a change of +8.1% yr over yr.
- Income by Finish Markets- Chemical and superior supplies: $385 million in comparison with the $385.60 million common estimate based mostly on two analysts. The reported quantity represents a change of +1.1% yr over yr.
- Web Income- Agilent Crosslab Group: $426 million versus $431.46 million estimated by two analysts on common. In comparison with the year-ago quarter, this quantity represents a +5.5% change.
- Income by Finish Markets- Environmental and Forensics: $164 million versus the two-analyst common estimate of $167.03 million. The reported quantity represents a year-over-year change of -6.3%.
- Web Income- Life Sciences and Utilized Markets Group: $833 million versus the two-analyst common estimate of $819.25 million. The reported quantity represents a year-over-year change of -10.2%.
- Web Income- Diagnostics and Genomics Group: $442 million in comparison with the $417.75 million common estimate based mostly on two analysts. The reported quantity represents a change of +24.2% yr over yr.
- Income by Finish Markets- Meals: $152 million versus $158.98 million estimated by two analysts on common. In comparison with the year-ago quarter, this quantity represents a -2.6% change.
View all Key Company Metrics for Agilent here>>>
Shares of Agilent have returned +2.8% over the previous month versus the Zacks S&P 500 composite’s +2.1% change. The inventory at the moment has a Zacks Rank #4 (Promote), indicating that it might underperform the broader market within the close to time period.
Zacks’ Analysis Chief Names “Inventory Most More likely to Double”
Our group of consultants has simply launched the 5 shares with the best chance of gaining +100% or extra within the coming months. Of these 5, Director of Analysis Sheraz Mian highlights the one inventory set to climb highest.
This high choose is among the many most revolutionary monetary corporations. With a fast-growing buyer base (already 50+ million) and a various set of innovative options, this inventory is poised for giant beneficial properties. After all, all our elite picks aren’t winners however this one might far surpass earlier Zacks’ Shares Set to Double like Nano-X Imaging which shot up +129.6% in little greater than 9 months.
Free: See Our Top Stock And 4 Runners Up
Agilent Technologies, Inc. (A) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially mirror these of Nasdaq, Inc.
